ATE352301T1 - Antineoplastische zusammensetzungen - Google Patents

Antineoplastische zusammensetzungen

Info

Publication number
ATE352301T1
ATE352301T1 AT04750108T AT04750108T ATE352301T1 AT E352301 T1 ATE352301 T1 AT E352301T1 AT 04750108 T AT04750108 T AT 04750108T AT 04750108 T AT04750108 T AT 04750108T AT E352301 T1 ATE352301 T1 AT E352301T1
Authority
AT
Austria
Prior art keywords
antineoplastic compositions
antineoplastic
compositions
Prior art date
Application number
AT04750108T
Other languages
English (en)
Inventor
James J Gibbons Jr
Gary Dukart
Matthew L Sherman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE352301T1 publication Critical patent/ATE352301T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04750108T 2003-04-22 2004-04-14 Antineoplastische zusammensetzungen ATE352301T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46449803P 2003-04-22 2003-04-22

Publications (1)

Publication Number Publication Date
ATE352301T1 true ATE352301T1 (de) 2007-02-15

Family

ID=33310901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04750108T ATE352301T1 (de) 2003-04-22 2004-04-14 Antineoplastische zusammensetzungen

Country Status (27)

Country Link
US (1) US20040258662A1 (de)
EP (1) EP1615640B1 (de)
JP (1) JP2006524246A (de)
KR (1) KR20060006058A (de)
CN (1) CN1777424A (de)
AR (1) AR044039A1 (de)
AT (1) ATE352301T1 (de)
AU (1) AU2004231720A1 (de)
BR (1) BRPI0409632A (de)
CA (1) CA2519338A1 (de)
CL (1) CL2004000836A1 (de)
CO (1) CO5630033A2 (de)
CR (1) CR7993A (de)
DE (1) DE602004004520T2 (de)
DK (1) DK1615640T3 (de)
EC (1) ECSP056114A (de)
ES (1) ES2279407T3 (de)
HK (1) HK1081463A1 (de)
MX (1) MXPA05010582A (de)
NO (1) NO20054412L (de)
PL (1) PL1615640T3 (de)
PT (1) PT1615640E (de)
RU (1) RU2005136222A (de)
TW (1) TW200503753A (de)
UA (1) UA80756C2 (de)
WO (1) WO2004093854A2 (de)
ZA (1) ZA200508574B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
NZ560840A (en) * 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
WO2007056439A1 (en) * 2005-11-08 2007-05-18 Collegium Pharmaceutical, Inc. Salts of methylene blue and its derivatives
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2656844T3 (en) 2008-06-17 2015-03-02 Wyeth Llc ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
AU2010234968B2 (en) 2009-04-06 2015-05-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US9278090B2 (en) * 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
AU2001283139A1 (en) * 2000-08-11 2002-02-25 Wyeth Method of treating estrogen receptor positive carcinoma
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
DK1635830T3 (da) * 2002-09-17 2009-02-23 Wyeth Corp Granulatformulering af rapamycinesteren CCI-779

Also Published As

Publication number Publication date
DE602004004520D1 (de) 2007-03-15
ZA200508574B (en) 2007-04-25
BRPI0409632A (pt) 2006-04-25
CA2519338A1 (en) 2004-11-04
KR20060006058A (ko) 2006-01-18
DE602004004520T2 (de) 2007-11-08
WO2004093854A2 (en) 2004-11-04
WO2004093854A3 (en) 2005-02-03
DK1615640T3 (da) 2007-03-12
EP1615640B1 (de) 2007-01-24
TW200503753A (en) 2005-02-01
UA80756C2 (en) 2007-10-25
PL1615640T3 (pl) 2007-05-31
NO20054412D0 (no) 2005-09-23
NO20054412L (no) 2005-11-21
MXPA05010582A (es) 2005-11-23
CN1777424A (zh) 2006-05-24
CR7993A (es) 2006-05-26
PT1615640E (pt) 2007-04-30
CL2004000836A1 (es) 2005-03-04
RU2005136222A (ru) 2006-03-20
HK1081463A1 (en) 2006-05-19
AR044039A1 (es) 2005-08-24
EP1615640A2 (de) 2006-01-18
ES2279407T3 (es) 2007-08-16
AU2004231720A1 (en) 2004-11-04
CO5630033A2 (es) 2006-04-28
US20040258662A1 (en) 2004-12-23
ECSP056114A (es) 2006-03-01
JP2006524246A (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
ATE352301T1 (de) Antineoplastische zusammensetzungen
FR2862654B1 (fr) Composition amylacee filmogene
DE602004018654D1 (de) Se
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
IS8309A (is) Lyfjablöndur
DE602004007143D1 (de) Härtbare perfluorelastomerzusammensetzungen
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
DE10393374D2 (de) Zusammensetzung
SE0500163L (sv) Sammansättning
ATE417648T1 (de) Stifte zusammensetzungen
ATE539138T1 (de) Schmierstoffzusammensetzungen
DK1587478T3 (da) Farmaceutisk sammensætning
AT502792A5 (de) Düsenanpressvorrichtung
FR2863890B1 (fr) Composition immunostimulante
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
DE602004004388D1 (de) Verdickbare zusammensetzungen
DK1704213T3 (da) Petroleumpræparat
DE602004004176D1 (de) Arbeitsgerät
ATE504290T1 (de) Zusammensetzungen mit neramexan
ATE342335T1 (de) Bleichmittelzusammensetzungen
ATE517662T1 (de) Stiftzusammensetzungen
ATE365529T1 (de) Schweisshemmende zusammensetzungen
DE502004007959D1 (de) Prolinylarylacetamide
DE112004002110D2 (de) Behälter-Deckel-Kombination
ITMI20030198A1 (it) Composizioni espandenti

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1615640

Country of ref document: EP

REN Ceased due to non-payment of the annual fee